secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001193125-26-191944
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Pharmaceuticals appoints Dr. Prakash Raman to Board of Directors
----------------------------------------------------------------------

- Dr. Raman appointed as Class II director effective April 28, 2026; term expires at 2028 annual meeting.
- He brings over 20 years of biopharma experience; currently CEO of InduPro Therapeutics.
- Received initial equity grants: option for 24,150 shares vesting monthly over 3 years, plus 2,911 shares vesting June 11, 2026.
- Company highlights lead program palazestrant in two Phase 3 trials with OPERA-01 data expected fall 2026.
- Board determined Dr. Raman is independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526191944/0001193125-26-191944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526191944/olma-20260427.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-191944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer